SCHEMBL6650007

SCHEMBL6650007

CCC(=O)Oc1ccc(CN(Cc2ccccn2)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
TSHR P16473 2/20 0.45
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HTT P42858 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 2/20 0.41
OPRK1 P41145 1/20 0.41
ELANE P08246 1/20 0.40
RECQL P46063 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249245 0.85 HDAC3 (0.47) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL4064665 0.84 HDAC3 (0.46) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL6018297 0.83 HDAC3 (0.46) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL6018138 0.83 HDAC3 (0.47) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL4932966 0.83 HDAC3 (0.53) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL3314672 0.82 ALDH1A1 (0.45) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL27532478 0.82 L3MBTL1 (0.46) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL4939432 0.81 HDAC3 (0.51) HDAC3HDAC1HDAC2NCOR2TSHR
SCHEMBL27439189 0.81 TRPM8 (0.55) TRPM8HDAC3HDAC1HDAC2NCOR2
SCHEMBL30441829 0.78 HDAC3 (0.44) TRPM8HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound KUREHA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389460-A1 CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND Kureha Chemical Industry Co., Ltd. (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound CXCR4, CXCR1, CXCR2 TRPM8 2359/4885HDAC3 1135/4885HDAC1 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.